Siragen Pharmaceuticals spinoff from Neurogeneration, files multiple patents

Following rapid development with its drug discovery program, Neurogeneration announces it was spinning off Siragen Pharmaceuticals, Inc., dedicated to expand its small molecules discoveries to treat neurodegenerative disorders like Alzheimers’disease. Siragen’s co-founders, Drs Kagalwala and Levesque, will continue in their roles as CSO and CEO respectively. The creation of Siragen Pharmaceuticals coincides with the recent filing of patents for its proprietary molecules, and follows a seed investment from private investors. Neurogeneration remains committed to its clinical cell therapy program for Parkinson’s disease and other degenerative disorders of the Central Nervous System.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s